louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01915849: Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus
Official title: A Randomized, Double-blinded, Placebo-controlled, Crossover Trial to Assess the Effect of Orally Administered LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Type 2 Diabetes Mellitus
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2013-08-05
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The purpose of the study was to assess the effect of LIK066 on intestinal glucose absorption immediately after a single dose (immediate effect) and 6 hours following the dose (after multiple daily doses; sustained effect) in patients with type 2 diabetes mellitus (T2DM).


Eligibility criteria: Inclusion Criteria:

* Patients, age 18-65 years, must have been diagnosed with T2DM at least 6 months prior to screening with HbA1c 6.5 to 10.0%, inclusive, at screening.
* Fasting plasma glucose ≤250mg/dL at screening.
* If treated with metformin, patients must be on a stable dose for 12 weeks prior to randomization and maintain the dose until the end of the study.

Exclusion Criteria:

* Patients with type 1 diabetes mellitus.
* Patients with history of acute diabetic complications within the 6 months prior to screening.
* Pregnant or nursing (lactating) women.
* Women of child-bearing potential unless they are using effective methods of contraception during dosing of study treatment.
* Patients with signs or symptoms of significant diabetic complications.
* Patients treated with certain blood pressure or lipid lowering medications unless patients have been on stable doses for the 12 weeks prior to dosing.
* History of drug or alcohol abuse within the 12 months prior to dosing.
* Any surgical or medical condition, acute or unstable chronic disease which may, based on the investigator's opinion, jeopardize the patient in case of participation in the study.

Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: Area Under the Postprandial Curve (AUC) for Rate of Appearance (Ra) of Exogenous Glucose
timeFrame: Day 1 and Day 4 (pre-meal, every half hour till 5 hour on Day 1 and Day 4)
Secondary outcomes:
Other outcomes:
Locations:
city: Chula Vista
country: United States
facility: Novartis Investigative Site
state: California
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
Clinical trial NCT01809249: Causes of Disqualification of Egyptian Potential Living Liver Donors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Donors Safety
Keywords: Living donor liver transplantation
Donar safety
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2013-03-12
Enrollment: 192
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: potential living liver donors

Brief summary: Due to absence of Deceased-donors in Egypt, Living-donor liver transplantation (LDLT) has emerged as an option to the traditional deceased-donor transplantation procedure. But there is an essential risk related to liver resection for healthy donors.

Detailed description: The aim of this work is to identify and analyze the causes of disqualification of potential Egyptian living liver-donors in a University based liver transplant program

Eligibility criteria: Inclusion Criteria:

* All potential living liver donors in the period from June 2010 to June 2012

  1. Age between 18 and 50 years
  2. Relationship within 3rd degree of consanguinity with recipient or spouse.
  3. The donor-recipient pair must be blood group compatible.
  4. An informed consent should be obtained.

Exclusion Criteria:

* Patients with nknown mrsdical or surgical history that interfere with donation

  * Underlying medical condition (diabetes, cardiopulmonary disease, etc.).
  * ABO incompatibility

Primary outcomes:
measure: causes of disqualification of potential Egyptian living liver-donors
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams Center For Organ Transplantation (ASCOT),Ain Shams university
Study officials:
References:
Clinical trial NCT00754949: Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis
Official title: A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical and Anti-Microbial Efficacy and Safety of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone in the Treatment of Subjects With Blepharoconjunctivitis
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Blepharoconjunctivitis
Keywords: Blepharoconjunctivitis,
Ophthalmology
Lead sponsor: Sun Pharmaceutical Industries Limited
Sponsor class: INDUSTRY
First posted: 2008-09-18
Enrollment: 0
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if AzaSite Plus is effective and safe for the treatment of blepharoconjunctivitis compared to AzaSite alone and Dexamethasone alone.


Eligibility criteria: Inclusion Criteria:

* Have a clinical diagnosis of blepharoconjunctivitis
* Must be willing to discontinue contact lens wear for the duration of the study
* Have best corrected visual acuity of 6/24 in both eyes
* Have IOP less than or equal to 25 mmHg in either eye

Exclusion Criteria:

* Have known sensitivity or poor tolerance to any component of the study medications
* Have a history of eyelid and/or ocular surgery and/or have had ocular surgical intervention within 6 months prior to visit 1 or during the study and/or a history of refractive surgery within 6 months
* Have worn contact lenses 72 hours prior to visit 1 and/or need to wear contact lenses for the duration of the study
* Have used any topical ophthalmic solutions including tear substitutes within 2 hours of enrollment
* Use of any eye make-up during the study
* Have any uncontrolled systemic disease or debilitating disease
* Have been diagnosed with glaucoma
* Have any clinically significant cardiovascular disorders
* Have any history of liver or kidney disease resulting in persisting dysfunction
* Have prior (within 30 days of beginning study treatment) or anticipated concurrent use of an investigational drug or device

Primary outcomes:
measure: Resolution of the clinical signs and symptoms.
timeFrame: 2 weeks
Secondary outcomes:
measure: Bacterial eradication
timeFrame: 2 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00671749: Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
Official title: A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Acne Vulgaris
Lead sponsor: Galderma R&D
Sponsor class: INDUSTRY
First posted: 2008-05-05
Enrollment: 100
Sex: ALL
Minimum age (years): 12
Maximum age (years): 35
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is to determine the efficacy and safety of 12 week treatment with Differin® Gel 0.3% applied in the evening, in combination with Duac® (Clindamycin/Benzoyl Peroxide Gel) applied in the morning, in Subjects with Acne vulgaris.

Detailed description: Same as above.

Eligibility criteria: Inclusion Criteria:

1. Subjects with a minimum of 20 inflammatory lesions on the face;
2. Subjects with a minimum of 15 and a maximum of 100 non-inflammatory lesions (open and closed comedones) on the face, excluding the nose;
3. Subject has a Global Severity Assessment

Exclusion Criteria:

1. Subjects with more than three nodulo-cystic lesions

Primary outcomes:
measure: Percent Change From Baseline in Total Lesion Counts
timeFrame: 6 and 12 weeks
Secondary outcomes:
measure: Global Severity Assessment Success
timeFrame: 6 and 12 weeks
measure: Global Assessment of Improvement From Baseline
timeFrame: 12 weeks
measure: Worst Post Baseline Tolerability Assessment - Erythema
timeFrame: 12 weeks
measure: Worst Post Baseline Tolerability Assessment - Scaling
timeFrame: 12 weeks
measure: Worst Post Baseline Tolerability Assessment - Dryness
timeFrame: 12 weeks
measure: Worst Post Baseline Tolerability Assessment - Burning/Stinging
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: Center for Dermatology and Laser Surgery
state: California
city: Louisville
country: United States
facility: Derm Research, P.L.L.C.
state: Kentucky
city: Warren
country: United States
facility: Brodell Medical
state: Ohio
city: Portland
country: United States
facility: Northwest Cutaneous Research Specialists
state: Oregon
Study officials:
affiliation: Galderma R&D
name: Ron W Gottschalk, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03705949: Impact of 0.1% and 0.2% Sodium Hyaluronate on Postoperative Discomfort Following Phacoemulsification Surgery
Official title: Impact of 0.1% Sodium Hyaluronate and 0.2% Sodium Hyaluronate on Postoperative Discomfort Following Cataract Extraction Surgery, a Comparative Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cataract
Lead sponsor: Democritus University of Thrace
Sponsor class: OTHER
Collaborators: name: Naval Hospital, Athens
name: George Papanicolaou Hospital
name: Athinaiki General Clinic
First posted: 2018-10-15
Enrollment: 180
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Primary objective of the study is the assessment of the patients' discomfort following cataract extraction surgery by means of phacoemulsification and intraocular lens implantation.

Detailed description: Participants will be recruited from the Cataract Service of the University Hospital of Alexandroupolis (UHA), the Naval Hospital in Athens, the Papanikolaou General Hospital in Thessaloniki, and Athinaiki General Clinic in Athens in a consecutive-if-eligible basis. By means of a custom computer randomization program all participants will randomly populate either study group \[who will receive fixed combination of tobramycin and dexamethasone (FCTD), (Tobradex, Alcon, Greece) quid for 3 weeks and 0.2 % sodium hyaluronate (Hylogel, Pharmex, Greece) quid for 6 weeks\], and control group \[who will receive Tobradex quid for 3 weeks and 0.1 % sodium hyaluronate (Hylocomod) quid for 6 weeks\].

Eligibility criteria: Inclusion Criteria:

* Diagnosis of senile cataract with stage 2 or 3 nuclear opalescence according to the - Lens Opacities Classification System III (LOCS-3) grading scale

Exclusion Criteria:

1. Diagnosis or evidence of dry-eye-disease (DED)
2. IOP-lowering medications
3. Former incisional surgery
4. Former diagnosis of corneal disease
5. Diabetes
6. Autoimmune diseases
7. Mental diseases

Primary outcomes:
measure: Surface Discomfort Index
timeFrame: 6 weeks
Secondary outcomes:
measure: Break up time
timeFrame: 6 weeks
measure: Central Corneal Sensitivity
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Alexandroupolis
country: Greece
facility: University Hospital of Alexandroupolis
state: Evros
Study officials:
affiliation: University Hospital of Alexandroupolis, Democritus University of Thrace
name: Georgios Labiris, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Ntonti P, Panagiotopoulou EK, Karastatiras G, Breyannis N, Tsironi S, Labiris G. Impact of 0.1% sodium hyaluronate and 0.2% sodium hyaluronate artificial tears on postoperative discomfort following cataract extraction surgery: a comparative study. Eye Vis (Lond). 2019 Feb 11;6:6. doi: 10.1186/s40662-019-0131-8. eCollection 2019.
Clinical trial NCT01449149: Proton Radiation for Chordomas and Chondrosarcomas
Official title: Proton Radiation For Chordomas and Chondrosarcomas
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Chordomas
Chondrosarcomas
Keywords: Age 18 or greater
No prior radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2011-10-10
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objectives of this study are 1) To evaluate the feasibility and acute side effects of proton therapy for chordomas and chondrosarcomas and 2) To evaluate clinical outcomes and long term side effects of proton beam radiation for treatment of chordomas and chondrosarcomas.

Detailed description: This trial will be conducted in two phases: a feasibility then a phase II trial. Once feasibility and safety are established in the first 12 pts. the phase II study will begin. Proton therapy at standard doses is not known to improve clinical outcome but will likely reduce fatigue and toxicity.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed diagnosis of chordoma or chondrosarcoma.
* Patients must have no evidence of metastatic disease based on routine imaging (CT or MRI of the chest/abdomen/pelvis, bone scan, etc.)
* Patients must have an ECOG score equal to or less than 2.
* Age ≥ 18 years.
* Patients must be able to provide informed consent.
* Adequate bone marrow function: WBC ≥ 4000/mm3, platelets ≥ 100, 000mm3
* Women of child-bearing potential as long as she agrees to use a recognized method of birth control (e.g. oral contraceptive , IUD, condoms or other barrier methods etc.) Hysterectomy or menopause must be clinically documented.
* Tumors arising in the skull and spine.

Exclusion Criteria:

* Prior or simultaneous malignancies within the past two years (other than cutaneous squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma)
* Patients with the following histologies are excluded: melanoma , other soft tissue or bony sarcomas, giant cell tumor aneurismal bone cyst or metastatic lesions from other histologies.
* Pregnant women.
* Actively being treated on any other therapeutic research study.
* Tumors arising outside of the CNS.

Primary outcomes:
measure: Feasibility of proton RT for chordomas and chondrosarcomas
timeFrame: Up to 10 days
measure: Acute Toxicity
timeFrame: 90 days
Secondary outcomes:
measure: Late toxicity
timeFrame: 90 days
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Abramson Cancer Center of the University of Pennsylvania
state: Pennsylvania
Study officials:
References:
Clinical trial NCT00658749: A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma
Official title: A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Asthma
Keywords: AIR645
Altair Therapeutics
IL4
IL13
IL-4
IL-13
Lead sponsor: Altair Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2008-04-15
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a phase one study to evaluate the safety, tolerability, and bioavailability of nebulized AIR645.


Eligibility criteria: Inclusion Criteria\*:

* Good General Health (with or without allergic rhinitis and/or controlled asthma)
* Non-smoker for at least 2 years
* Normal lung function (DLCO)
* Able to provide informed consent and to understand and comply with the requirements of the study

Exclusion Criteria\*:

* Clinically significant medical history or condition which precludes participation
* Clinically significant ECG abnormality
* Clinically significant VS or PE abnormality
* Clinically significant screening lab abnormality
* Abnormal lung function (FEV1 \<80% predicted)
* Respiratory infection within 14 days of randomization
* HBV, HCV, or HIV
* Breastfeeding or pregnant female
* History of alcohol abuse or illicit drug use within past 24 months
* Use of any tobacco or nicotine-containing product within past 6 months
* Use of any herbal supplement, over-the-counter drug, or prescription drug that is not allowed per protocol
* Use of any investigational drug within past 30 days
* Use of any investigational monoclonal antibody or recombinant protein within past 90 days
* Donation of plasma within past 7 days
* Donation or loss of whole blood within past 56 days

  * Simplified list of I/E criteria; unabridged list available upon request.

Primary outcomes:
measure: Measures of the safety and tolerability of AIR645 include documentation of adverse events and changes (compared to baseline) in vital signs, physical examination, pulmonary function tests, heart rhythm, and laboratory tests.
timeFrame: During dosing and for two weeks after dosing
Secondary outcomes:
measure: Bioavailability
timeFrame: During dosing and for two weeks after dosing
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Contract Research Organization (CRO) appointed by Altair Therapeutics--Altair's offices are in:
state: California
Study officials:
affiliation: Altair Therapeutics
name: Mike Hodges, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01518049: Clinical Validation of the Rating Scale for Psychotic Depression (RAS-PD)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Affective Disorders, Psychotic
Keywords: Affective Disorders, Psychotic
Psychometrics
Biological Markers
Lead sponsor: Aarhus University Hospital
Sponsor class: OTHER
First posted: 2012-01-25
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: inpatients or outpatients at Danish Psychiatric Hospitals fulfilling criteria for unipolar depression with psychotic symptoms.

Brief summary: The aim of this study is to develop a scale to measure the severity of depression with psychotic symptoms (psychotic depression). Furthermore, we hope to detect potential biomarkers (substances in the blood) which can aid in the detection of psychotic depression.

Main hypothesis: A clinically valid rating scale measuring the severity of psychotic depression can be developed.


Eligibility criteria: Inclusion Criteria:

* Fulfilling ICD-10 criteria DF32.3 or DF33.3
* At least 18 years old
* Legally competent
* Informed consent (oral \& written)

Exclusion Criteria:

* Insufficient Danish Language skills
* Moderate to severe dementia
* Abuse of psychoactive substances

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Unit for Psychiatric Research, Aalborg Psychiatric Hospital, Aarhus University Hospital
Study officials:
affiliation: Aahus University Hospital
name: Søren D Østergaard, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ostergaard SD, Pedersen CH, Uggerby P, Munk-Jorgensen P, Rothschild AJ, Larsen JI, Gotzsche C, Sondergaard MG, Bille AG, Bolwig TG, Larsen JK, Bech P. Clinical and psychometric validation of the psychotic depression assessment scale. J Affect Disord. 2015 Mar 1;173:261-8. doi: 10.1016/j.jad.2014.11.012. Epub 2014 Nov 18.
Clinical trial NCT01737749: Validation of Neurokeeper's Algorithm on Patients Undergoing Cardiac Surgery.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Stroke
Keywords: Stroke
Lead sponsor: Neurokeeper Technologies
Sponsor class: INDUSTRY
First posted: 2012-11-29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing cardiac surgery.

Brief summary: The primary objective of the study is to check the ability of Neurokeeper's algorithm system to detect and monitor changes in cerebral electrophysiological parameters as compared to clinical evaluation in patients undergoing cardiac surgery.

The secondary objectives is correlations of EEG + ERP measurements with clinical evaluations as assessed by NIHSS ThiS study is a prospective, open label, single arm, self control, single center study.

This study will be conducted in 50 subjects according to the inclusions/exclusions criteria.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years old.
* Patients undergoing cardiac surgery .

Exclusion Criteria:

* Previous major hemispheric stroke.
* Any known major hemispheric lesion.
* Significant movement disorder.
* Local skull or skin affliction which prevents electrodes application.
* Any known condition which in the opinion of the investigator may interfere with the protocol implementation.

Primary outcomes:
measure: Neurological detrioration detection
Secondary outcomes:
measure: Time from deterioration to detection
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Medical Center
Study officials:
affiliation: Rambam Health Care Campus
name: Moshe' Herskovitz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01177449: The Effect of Prolotherapy on Balance and Lumbar Flexibility in the Patients With a Sacralized L5 Vertebra
Official title: The Effect of Prolotherapy on Balance and Lumbar Flexibility in the Patients With a Sacralized L5 Vertebra
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lumbosacral Transitional Vertebra
Keywords: prolotherapy
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2010-08-09
Enrollment: 17
Sex: ALL
Minimum age (years): 16
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the effect of prolotherapy on balance and lumbar flexibility in the patients with a sacralized L5 vertebra. Evaluations for ability on balance include sensory organization test (SOT,) rhythmic weight shifting (RWS) and limits of stability (LOS.)

Detailed description: Lumbosacral transitional vertebra (LSTV) is a congenital variety of vertebral bony construction, which is most frequently presented as sacralized L5 or lumbarized S1. LSTV would alter the kinetics of the spine thus induce inadequate mobility and dynamic compensation. Patients with LSTV were commonly found when they visited clinicians for treatment of low back pain. Prolotherapy is a technique that stimulates the body to repair the painful area by assistance of injecting an otherwise non-pharmacological and non-active irritant solution into the body.

Eligibility criteria: Inclusion Criteria:

* patients with a sacralized L5 vertebra confirmed by X-ray images

Exclusion Criteria:

* neuromuscular injury
* visual deficit
* vestibular deficit
* cannot recognize the marks on the screen

Primary outcomes:
measure: sensory organization
timeFrame: 30 minutes
measure: rhythmic weight shifting
timeFrame: 30 minutes
measure: limits of stability
timeFrame: 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Guishan
country: Taiwan
facility: Department of Rehabilitation Medicine, Chang Gung Medical Foundation, Linkou Branch
state: Taoyuan County
Study officials:
affiliation: Department of Rehabilitation Medicine, Chang Gung Medical Foundation, Linkou Branch
name: Shih-Wei Chou, MD, PhD.
role: PRINCIPAL_INVESTIGATOR
References: